Log in

NYSEAMERICAN:OCXOncoCyte Stock Price, Forecast & News

$2.18
-0.17 (-7.23 %)
(As of 04/6/2020 08:39 AM ET)
Add
Compare
Today's Range
$2.11
Now: $2.18
$2.38
50-Day Range N/A
52-Week Range
$1.50
Now: $2.18
$5.60
Volume100,344 shs
Average Volume267,976 shs
Market Capitalization$136.19 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
OncoCyte Corporation focuses on the development and commercialization of novel and non-invasive blood and urine (liquid biopsy) diagnostic tests for the early detection of cancer. The company is developing diagnostic tests using genetic and protein markers expressed in various types of cancer. It develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancer. The company was founded in 2009 and is based in Alameda, California. OncoCyte Corporation is a subsidiary of BioTime, Inc.
Read More
OncoCyte logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.86 out of 5 stars


Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:OCX
CUSIPN/A
Phone(510) 775-0515

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees12
Market Cap$136.19 million
Next Earnings Date5/12/2020 (Estimated)
OptionableNot Optionable

Receive OCX News and Ratings via Email

Sign-up to receive the latest news and ratings for OCX and its competitors with MarketBeat's FREE daily newsletter.


OncoCyte (NYSEAMERICAN:OCX) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of OncoCyte?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OncoCyte in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for OncoCyte.

When is OncoCyte's next earnings date?

OncoCyte is scheduled to release its next quarterly earnings announcement on Tuesday, May 12th 2020. View our earnings forecast for OncoCyte.

How were OncoCyte's earnings last quarter?

OncoCyte Corp (NYSEAMERICAN:OCX) announced its quarterly earnings results on Wednesday, March, 25th. The biotechnology company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.09) by $0.06. View OncoCyte's earnings history.

What price target have analysts set for OCX?

2 analysts have issued 1-year target prices for OncoCyte's stock. Their forecasts range from $7.00 to $7.75. On average, they expect OncoCyte's share price to reach $7.38 in the next year. This suggests a possible upside of 238.3% from the stock's current price. View analysts' price targets for OncoCyte.

Has OncoCyte been receiving favorable news coverage?

Headlines about OCX stock have trended very negative this week, InfoTrie Sentiment Analysis reports. InfoTrie scores the sentiment of media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. OncoCyte earned a coverage optimism score of -3.3 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news aboutOncoCyte.

Are investors shorting OncoCyte?

OncoCyte saw a increase in short interest in the month of February. As of February 28th, there was short interest totaling 1,290,000 shares, an increase of 7.5% from the February 13th total of 1,200,000 shares. Based on an average trading volume of 293,200 shares, the days-to-cover ratio is presently 4.4 days. Currently, 2.7% of the company's stock are short sold. View OncoCyte's Current Options Chain.

Who are some of OncoCyte's key competitors?

What other stocks do shareholders of OncoCyte own?

Who are OncoCyte's key executives?

OncoCyte's management team includes the following people:
  • Mr. William Annett, Pres, CEO & Director (Age 65)
  • Mr. Mitchell S. Levine, Chief Financial Officer
  • Dr. Lyndal K. Hesterberg, Chief Scientific Officer
  • Mr. Albert P. Parker II, Chief Operating Officer
  • Dr. Michael D. West, Scientific Advisor, Co-CEO of Biotime,Inc. & Pres of Biotime,Inc. (Age 66)

What is OncoCyte's stock symbol?

OncoCyte trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "OCX."

How do I buy shares of OncoCyte?

Shares of OCX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is OncoCyte's stock price today?

One share of OCX stock can currently be purchased for approximately $2.18.

How big of a company is OncoCyte?

OncoCyte has a market capitalization of $136.19 million. OncoCyte employs 12 workers across the globe. View additional information about OncoCyte.

What is OncoCyte's official website?

The official website for OncoCyte is http://www.oncocyte.com/.

How can I contact OncoCyte?

OncoCyte's mailing address is 1010 Atlantic Ave Ste 102, ALAMEDA, CA 94501-1147, United States. The biotechnology company can be reached via phone at (510) 775-0515.

This page was last updated on 4/6/2020 by MarketBeat.com Staff

Featured Article: What is a price target?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel